Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2003;41:598-603
Published online before print February 17, 2003, doi: 10.1161/01.HYP.0000056524.35294.80
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/3/598    most recent
01.HYP.0000056524.35294.80v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fukuyama, K.
Right arrow Articles by Takeshita, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fukuyama, K.
Right arrow Articles by Takeshita, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*NITRIC OXIDE

(Hypertension. 2003;41:598.)
© 2003 American Heart Association, Inc.


Scientific Contributions

Downregulation of Vascular Angiotensin II Type 1 Receptor by Thyroid Hormone

Kae Fukuyama; Toshihiro Ichiki; Kotaro Takeda; Tomotake Tokunou; Naoko Iino; Satoko Masuda; Minako Ishibashi; Kensuke Egashira; Hiroaki Shimokawa; Katsuya Hirano; Hideo Kanaide; Akira Takeshita

From the Departments of Cardiovascular Medicine (K.F., T.I., K.T., T.T., N.I., S.M., M.I., K.E., H.S., A.T.) and Molecular Cardiology (K.H., H.K.), Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Correspondence to Toshihiro Ichiki, MD, Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, 812-8582 Fukuoka, Japan. E-mail ichiki{at}cardiol.med.kyushu-u.ac.jp

Thyroid hormone has a broad effect on cardiovascular system. 3,3',5-triiodo-L-thyronine (T3), a biologically active form of thyroid hormone, increases cardiac contractility. T3 causes arterial relaxation and reduction of systemic vascular resistance, resulting in an increase in cardiac output. However, the molecular mechanisms of vascular relaxation by T3 are incompletely characterized. We studied the effect of T3 on the angiotensin (Ang) II type 1 receptor (AT1R) expression in vascular smooth muscle cells. T3 dose-dependently decreased expression levels of AT1R mRNA, with a peak at 6 hours of stimulation. Binding assay using [125I]Sar1-Ile8-Ang II revealed that AT1R number was decreased by stimulation with T3 without changing the affinity to Ang II. T3 reduced calcium response of vascular smooth muscle cells to Ang II by 26%. AT1R promoter activity measured by luciferase assay was reduced by 50% after 9 hours of T3 administration. mRNA stability was also decreased by T3. Real-time quantitative reverse transcription–polymerase chain reaction and Western blot analysis revealed that AT1R mRNA and protein were downregulated in the aorta of T3-treated rats. These results suggest that T3 downregulates AT1R expression both at transcriptional and posttranscriptional levels, and attenuates biological function of Ang II. Our results suggest that downregulation of AT1R gene expression may play an important role for T3-induced vascular relaxation.


Key Words: hormones • receptors, angiotensin II • gene expression • mRNA stability • vascular relaxation




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Miyazaki, T. Ichiki, T. Hashimoto, K. Inanaga, I. Imayama, J. Sadoshima, and K. Sunagawa
SIRT1, a Longevity Gene, Downregulates Angiotensin II Type 1 Receptor Expression in Vascular Smooth Muscle Cells
Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1263 - 1269.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Ohtsubo, T. Ichiki, R. Miyazaki, K. Inanaga, I. Imayama, Y. Hashiguchi, J. Sadoshima, and K. Sunagawa
Inducible cAMP Early Repressor Inhibits Growth of Vascular Smooth Muscle Cell
Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1549 - 1555.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. S. Elton and M. M. Martin
Angiotensin II Type 1 Receptor Gene Regulation: Transcriptional and Posttranscriptional Mechanisms
Hypertension, May 1, 2007; 49(5): 953 - 961.
[Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
G. Fava, Y. Ueno, S. Glaser, H. Francis, S. DeMorrow, L. Marucci, M. Marzioni, A. Benedetti, J. Venter, B. Vaculin, et al.
Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP3/Ca2+-dependent downregulation of SRC/ERK1/2
Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1467 - C1475.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
P. K. Mehta and K. K. Griendling
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Fukuyama, T. Ichiki, I. Imayama, H. Ohtsubo, H. Ono, Y. Hashiguchi, A. Takeshita, and K. Sunagawa
Thyroid Hormone Inhibits Vascular Remodeling Through Suppression of cAMP Response Element Binding Protein Activity
Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2049 - 2055.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Sato, R. Nakamura, M. Satoh, K. Fujishita, S. Mori, S. Ishida, T. Yamaguchi, K. Inoue, T. Nagao, and Y. Ohno
Thyroid Hormone Targets Matrix Gla Protein Gene Associated With Vascular Smooth Muscle Calcification
Circ. Res., September 16, 2005; 97(6): 550 - 557.
[Abstract] [Full Text] [PDF]